Sanofi Pays Regeneron $1B Upfront to Add Four Long-Acting Immunology Antibodies to the Dupixent Alliance
- Sanofi and Regeneron expanded their alliance with $1 billion upfront and up to $7 billion in development, regulatory and commercial milestones.
- The deal adds four antibodies: clinical-stage long-acting IL-13 REGN20423, a long-acting IL-4xIL-13 bispecific and two preclinical long-acting antibodies against IL-4 pathway targets.
- Regeneron leads R&D, Sanofi leads global commercialization, and costs and profits split 50:50.
💡 Points
This is Sanofi buying a Dupixent successor from the one partner that already knows how to make that franchise work, ahead of the 2031 US patent expiry. Paying $1B for a Phase 1 antibody and three preclinical ones is really a bet on long-acting dosing as the differentiator against a crowded type 2 inflammation field. For Regeneron it is non-dilutive funding plus a reconfirmed partner; I'd watch whether Sanofi's other immunology assets get de-prioritized.
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D ↗